Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $82.6M | $149M | $272M | $527M | $872M | $1.48B | $2.35B |
| Revenue growth | — | 80.2% | 82.8% | 93.8% | 65.5% | 69.3% | 59.0% |
| Gross profit | $44.6M | $109M | $204M | $409M | $715M | $1.17B | $1.73B |
| Gross margin | 54.0% | 73.6% | 75.2% | 77.6% | 82.0% | 79.5% | 73.8% |
| Operating income | -$74.4M | -$15.1M | -$115M | -$68.7M | -$29.5M | $61.9M | $106M |
| Operating margin | -90.1% | -10.2% | -42.3% | -13.0% | -3.4% | 4.2% | 4.5% |
| Net income | -$72.1M | -$18.1M | -$108M | -$65.7M | -$23.5M | $126M | $128M |
| Net margin | -87.3% | -12.2% | -39.6% | -12.5% | -2.7% | 8.5% | 5.5% |
| EPS (diluted) | -$2.07 | -$0.51 | -$0.58 | -$0.32 | -$0.11 | $0.53 | $0.51 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$74.9M | -$2.48M | -$34.4M | -$26.5M | $73.5M | $251M | $300M |
| Capital expenditures | — | — | — | $7.20M | $26.5M | $52.8M | $243M |
| Free cash flow | — | — | — | -$33.7M | $47.0M | $198M | $57.4M |
| Share buybacks | $0.00 | $0.00 | $0.00 | $0.00 | $2.00M | $83.0M | $90.0M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.51M | $27.3M | $71.8M | $46.8M | $96.7M | $221M | $229M |
| Total assets | $205M | $119M | $421M | $366M | $441M | $708M | $2.15B |
| Total liabilities | $8.17M | $15.6M | $86.0M | $54.6M | $97.2M | $231M | $1.61B |
| Shareholders' equity | -$140M | -$147M | $335M | $312M | $344M | $477M | $541M |
| Retained earnings | $1.15M | -$171M | -$279M | -$345M | -$368M | -$242M | -$114M |
| Shares (wtd avg diluted) | 34.8M | 35.4M | 187M | 205M | 209M | 237M | 258M |
Every figure is extracted from Hims & Hers Health, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.